Next 10 |
home / stock / ipcif / ipcif news
TORONTO, ON / ACCESSWIRE / June 14, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI.H) (" Intellipharmaceutics " or the " Company "), announced today that its common stock, currently traded on the OTCQB market, is expected to be downgraded to the OTC Expert Market on J...
MJ Holdings Inc (MJNE) is expected to report for Q1 2024 Meritage Hospitality Group Inc. (MHGU) is expected to report $0.17 for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Luna Innovations Incorporated (LUNA) is expected to report $-0.01 for Q1 2024 Cano Health...
TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rel...
TORONTO, ON / ACCESSWIRE / February 26, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-re...
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release...
2024-01-02 17:54:30 ET More on Intellipharmaceutics Financial information for Intellipharmaceutics International For further details see: Intellipharmaceutics receives conditional approval to list on the TSX Venture Exchange
TORONTO, ON / ACCESSWIRE / January 2, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-releas...
2023-10-16 17:30:52 ET More on Intellipharmaceutics International Financial information for Intellipharmaceutics International For further details see: Intellipharmaceutics International GAAP EPS of -$0.06
TORONTO, ON / ACCESSWIRE / October 16, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-relea...
JPMorgan Chase & Co. (JPM) is expected to report $3.89 for Q3 2023 Unity Bancorp Inc. (UNTY) is expected to report $0.89 for Q3 2023 Wells Fargo & Company (WFC) is expected to report $1.25 for Q3 2023 Intellipharmaceutics International Inc (IPCIF) is expected to report for Q1 ...
News, Short Squeeze, Breakout and More Instantly...
Intellipharmaceutics International Inc Company Name:
IPCIF Stock Symbol:
OTCMKTS Market:
Intellipharmaceutics International Inc Website:
TORONTO, ON / ACCESSWIRE / June 14, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI.H) (" Intellipharmaceutics " or the " Company "), announced today that its common stock, currently traded on the OTCQB market, is expected to be downgraded to the OTC Expert Market on J...
MJ Holdings Inc (MJNE) is expected to report for Q1 2024 Meritage Hospitality Group Inc. (MHGU) is expected to report $0.17 for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Luna Innovations Incorporated (LUNA) is expected to report $-0.01 for Q1 2024 Cano Health...
TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - (" Intellipharmaceutics " or the " Company "), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-rel...